Wellington Management Group LLP Trims Holdings in Illumina, Inc. (NASDAQ:ILMN)

Wellington Management Group LLP trimmed its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 18.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,298 shares of the life sciences company's stock after selling 5,648 shares during the quarter. Wellington Management Group LLP's holdings in Illumina were worth $3,381,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ILMN. Capital World Investors increased its holdings in Illumina by 408.6% during the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock worth $2,408,721,000 after purchasing an additional 14,481,232 shares in the last quarter. Brown Advisory Inc. boosted its position in shares of Illumina by 54,220.9% during the fourth quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company's stock worth $255,586,000 after buying an additional 1,909,118 shares during the period. Norges Bank bought a new position in shares of Illumina during the fourth quarter worth about $228,714,000. Bessemer Group Inc. raised its position in Illumina by 32,837.5% in the 4th quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company's stock valued at $180,152,000 after buying an additional 1,344,038 shares during the last quarter. Finally, WCM Investment Management LLC raised its position in Illumina by 26.6% in the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock valued at $551,625,000 after buying an additional 867,673 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Insider Transactions at Illumina

In other news, CFO Ankur Dhingra bought 6,100 shares of the stock in a transaction dated Monday, May 12th. The stock was purchased at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the acquisition, the chief financial officer now owns 24,906 shares of the company's stock, valued at $2,022,616.26. The trade was a 32.44% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 2.60% of the company's stock.

Illumina Stock Performance

ILMN traded up $0.41 during mid-day trading on Friday, reaching $82.66. 1,614,255 shares of the company traded hands, compared to its average volume of 2,310,669. The company's fifty day moving average price is $77.81 and its 200-day moving average price is $105.08. The stock has a market capitalization of $13.09 billion, a P/E ratio of -10.76, a P/E/G ratio of 1.60 and a beta of 1.35. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. The business had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.03 billion. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The business's quarterly revenue was down 1.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.98 earnings per share. On average, sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

ILMN has been the topic of a number of recent research reports. Robert W. Baird lowered their target price on Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 5th. Stephens reaffirmed an "overweight" rating and set a $105.00 price target on shares of Illumina in a research report on Tuesday, May 20th. Barclays dropped their price objective on Illumina from $100.00 to $77.00 and set an "underweight" rating on the stock in a research note on Thursday, April 10th. Royal Bank of Canada dropped their price target on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a research report on Tuesday, April 8th. Finally, Hsbc Global Res lowered shares of Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Illumina presently has an average rating of "Moderate Buy" and a consensus price target of $128.84.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.